Dimension Therapeutics Company Profile (NASDAQ:DMTX)

About Dimension Therapeutics

Dimension Therapeutics logoDimension Therapeutics, Inc. is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa). The Company's gene therapy product candidates and programs are designed to provide a functional copy of an abnormal or missing gene using the advanced adeno-associated virus (AAV)-based vector delivery technology. DTX101 is the Company's lead gene therapy product candidate designed to deliver Factor IX (FIX), gene expression in patients with hemophilia B. DTX201 is its Factor VIII (FVIII) gene therapy program for the treatment of hemophilia A. DTX301 is its gene therapy product candidate designed for the treatment of patients with OTC deficiency. DTX401 is its gene therapy program for the treatment of patients with GSDIa.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: DMTX
  • CUSIP:
Key Metrics:
  • Previous Close: $1.90
  • 50 Day Moving Average: $3.76
  • 200 Day Moving Average: $5.69
  • 52-Week Range: $25,043,000.00 - $1.65
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.79
  • P/E Growth: 0.00
  • Market Cap: $47.58M
  • Outstanding Shares: 25,043,000
  • Beta: 3.97
Profitability:
  • Net Margins: -464.39%
  • Return on Equity: -50.07%
  • Return on Assets: -37.10%
Debt:
  • Debt-to-Equity Ratio: 0.07%
  • Current Ratio: 5.43%
  • Quick Ratio: 5.43%
Additional Links:
Companies Related to Dimension Therapeutics:

Analyst Ratings

Consensus Ratings for Dimension Therapeutics (NASDAQ:DMTX) (?)
Ratings Breakdown: 3 Hold Ratings, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $10.83 (470.18% upside)

Analysts' Ratings History for Dimension Therapeutics (NASDAQ:DMTX)
Show:
DateFirmActionRatingPrice TargetDetails
2/2/2017Jefferies Group LLCReiterated RatingBuy$7.00View Rating Details
1/31/2017Canaccord GenuitySet Price TargetBuy$20.00View Rating Details
1/31/2017Cantor FitzgeraldDowngradeOverweight -> Neutral$32.00 -> $3.00View Rating Details
8/21/2016Chardan CapitalSet Price TargetHold$10.00View Rating Details
3/30/2016Goldman Sachs Group, Inc. (The)DowngradeBuy -> Neutral$10.00View Rating Details
3/29/2016Citigroup Inc.Lower Price TargetBuy$18.00 -> $15.00View Rating Details
12/3/2015Wells Fargo & CompanyInitiated CoverageOutperformView Rating Details
11/6/2015Roth CapitalInitiated CoverageBuy$31.00View Rating Details
(Data available from 2/20/2015 forward)

Earnings

Earnings History for Dimension Therapeutics (NASDAQ:DMTX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/22/2017        
5/12/2016Q116($0.57)($0.38)$2.24 million$2.21 millionViewN/AView Earnings Details
3/24/2016($0.38)($0.45)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Dimension Therapeutics (NASDAQ:DMTX)
Current Year EPS Consensus Estimate: $-2.01 EPS
Next Year EPS Consensus Estimate: $-2.42 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.43)($0.43)($0.43)
Q3 20161($0.53)($0.53)($0.53)
Q4 20161($0.60)($0.60)($0.60)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Dimension Therapeutics (NASDAQ:DMTX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Dimension Therapeutics (NASDAQ:DMTX)
Insider Ownership Percentage: 2.18%
Institutional Ownership Percentage: 85.43%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/7/2016K. Reed ClarkSVPSell5,000$10.00$50,000.00View SEC Filing  
10/27/2015Rishi GuptaDirectorBuy200,000$13.00$2,600,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Dimension Therapeutics (NASDAQ:DMTX)
DateHeadline
News IconDimension Therapeutics Inc DMTX Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300 (NASDAQ:DMTX)
www.bioportfolio.com - February 20 at 11:31 AM
News IconAre Analysts Optimistic About Where Dimension Therapeutics Inc (NASDAQ:DMTX) is Heading? - Winfield Review (NASDAQ:DMTX)
winfieldreview.com - February 16 at 2:46 PM
News IconIs The Sell-Side Predicting That Dimension Therapeutics Inc (NASDAQ:DMTX) Will Move Higher? - Winfield Review (NASDAQ:DMTX)
winfieldreview.com - February 16 at 2:46 PM
4-traders.com logoNewman Ferrara LLP : Announces Corporate Governance Investigation of Dimension Therapeutics Inc. (NASDAQ:DMTX)
www.4-traders.com - February 14 at 5:38 PM
News IconNASDAQ:DMTX Shareholder Notice: Investigation over potential Securities Laws Violations by Dimension Therapeutics Inc (NASDAQ:DMTX)
www.groundreport.com - February 14 at 5:38 PM
finance.yahoo.com logoNewman Ferrara LLP Announces Corporate Governance Investigation of Dimension Therapeutics Inc. (NASDAQ:DMTX)
finance.yahoo.com - February 14 at 5:37 PM
finance.yahoo.com logoDimension Therapeutics Elects Dr. John A. Hohneker to Its Board of Directors (NASDAQ:DMTX)
finance.yahoo.com - February 7 at 5:53 PM
sbwire.com logoDimension Therapeutics Inc (NASDAQ:DMTX) Investor Investigation Concerning Potential Violations of Securities Laws (NASDAQ:DMTX)
www.sbwire.com - February 6 at 4:48 PM
businesswire.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Dimension ... (NASDAQ:DMTX)
www.businesswire.com - February 2 at 5:11 PM
News IconDimension Therapeutics, Inc. (NASDAQ:DMTX) has the current quarter growth of (NASDAQ:DMTX)
cote-ivoire.com - February 2 at 5:11 PM
News IconThe Dimension Therapeutics, Inc. (DMTX) Receives Consensus Recommendation of "Buy" from Brokerages (NASDAQ:DMTX)
hoyentv.com - February 2 at 5:11 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Dimension Therapeutics, Inc. (NASDAQ:DMTX)
finance.yahoo.com - February 2 at 5:11 PM
marketexclusive.com logoAnalyst Activity – Jefferies Group LLC Reiterates Buy on Dimension Therapeutics (NASDAQ:DMTX) (NASDAQ:DMTX)
marketexclusive.com - February 2 at 3:23 AM
News IconIncrease in Volatility Draws Attention to Shares of Dimension Therapeutics, Inc. (NASDAQ:DMTX) - Wall Street Beacon (NASDAQ:DMTX)
wsbeacon.com - February 1 at 5:17 PM
News IconDimension Therapeutics Inc (NASDAQ:DMTX): A Recovery Play? - Insider Financial (NASDAQ:DMTX)
www.insiderfinancial.com - February 1 at 5:17 PM
streetinsider.com logoDimension Therapeutics (DMTX) Reports Prelim. Data From Ongoing Phase 1/2 Clinical Program for DTX101 (NASDAQ:DMTX)
www.streetinsider.com - January 31 at 10:27 PM
us.rd.yahoo.com logoDimension Announces Interim Topline Results from Ongoing Phase 1/2 Clinical Program for DTX101, Dimension’s Lead AAV Product Candidate in Development for Adult Patients with Moderate/Severe to Severe Hemophilia B (NASDAQ:DMTX)
us.rd.yahoo.com - January 31 at 10:27 PM
streetinsider.com logoForm 8-K Dimension Therapeutics, For: Jan 31 (NASDAQ:DMTX)
www.streetinsider.com - January 31 at 5:25 PM
marketexclusive.com logoDimension Therapeutics, Inc. (NASDAQ:DMTX) Files An 8-K Regulation FD Disclosure (NASDAQ:DMTX)
marketexclusive.com - January 31 at 5:25 PM
finance.yahoo.com logoDimension Therapeutics downgraded by Cantor Fitzgerald (NASDAQ:DMTX)
finance.yahoo.com - January 31 at 5:25 PM
News IconDimension Therapeutics Inc DMTX Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:DMTX)
www.bioportfolio.com - January 22 at 9:44 PM
zacks.com logoFalling Earnings Estimates Signal Weakness Ahead for MiMedx Group (MDXG) (NASDAQ:DMTX)
www.zacks.com - January 20 at 6:00 PM
4-traders.com logoDIMENSION THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K) (NASDAQ:DMTX)
www.4-traders.com - January 20 at 6:00 PM
biz.yahoo.com logoDIMENSION THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:DMTX)
biz.yahoo.com - January 20 at 6:00 PM
4-traders.com logoDimension Therapeutics : Announces FDA Acceptance of Investigational New Drug Application for DTX301 to Treat OTC Deficiency (NASDAQ:DMTX)
www.4-traders.com - December 14 at 5:48 PM
insidermonkey.com logoIs Dimension Therapeutics Inc (DMTX) Going to Burn These Hedge Funds? (NASDAQ:DMTX)
www.insidermonkey.com - December 14 at 3:27 AM
finance.yahoo.com logoDimension Therapeutics Announces FDA Acceptance of Investigational New Drug Application for DTX301 to Treat OTC Deficiency (NASDAQ:DMTX)
finance.yahoo.com - December 13 at 11:31 AM
tmcnet.com logoDimension Therapeutics Announces Presentation at the 58th American Society of Hematology (ASH) Annual Meeting (NASDAQ:DMTX)
it.tmcnet.com - December 5 at 12:00 PM
globenewswire.com logoFirst COMP Positive Opinion for a Treatment in Development for GSDIa (NASDAQ:DMTX)
globenewswire.com - November 29 at 5:42 PM
investingnews.com logoDimension Therapeutics Receives Positive Opinion for European Orphan Drug Designation of DTX401 for the Treatment of Glycogen Storage Disease Type Ia (NASDAQ:DMTX)
investingnews.com - November 29 at 5:42 PM
us.rd.yahoo.com logoDimension Therapeutics Receives Positive Opinion for European Orphan Drug Designation of DTX401 for the Treatment of Glycogen Storage Disease Type Ia (GSDIa) (NASDAQ:DMTX)
us.rd.yahoo.com - November 29 at 5:42 PM
us.rd.yahoo.com logo8:03 am Dimension Therapeutics announces that the COMP of the EMA has issued a positive opinion recommending DTX401 for designation as an orphan medicinal product for the treatment of Glycogen Storage Disease Type Ia (NASDAQ:DMTX)
us.rd.yahoo.com - November 29 at 5:42 PM
finance.yahoo.com logoDIMENSION THERAPEUTICS, INC. Financials (NASDAQ:DMTX)
finance.yahoo.com - November 18 at 3:59 PM
News IconDimension Therapeutics, Inc. DMTX Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:DMTX)
www.bioportfolio.com - November 18 at 12:41 PM
capitalcube.com logoETFs with exposure to Dimension Therapeutics, Inc. : November 14, 2016 (NASDAQ:DMTX)
www.capitalcube.com - November 14 at 4:51 PM
insidermonkey.com logoHere’s What We Are Looking For From The Upcoming Dimension Therapeutics Inc (DMTX) Data (NASDAQ:DMTX)
www.insidermonkey.com - November 14 at 4:51 PM
sg.finance.yahoo.com logoDimension Therapeutics reports 3Q loss (NASDAQ:DMTX)
sg.finance.yahoo.com - November 11 at 12:00 PM
capitalcube.com logoDimension Therapeutics, Inc. :DMTX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 11, 2016 (NASDAQ:DMTX)
www.capitalcube.com - November 11 at 12:00 PM
tmcnet.com logoDimension Therapeutics Reports Recent Corporate Progress and Third Quarter 2016 Financial Results (NASDAQ:DMTX)
www.tmcnet.com - November 10 at 8:49 PM
News IconDimension Therapeutics Inc. (DMTX) Receives $16.33 Consensus Price Target from Analysts (NASDAQ:DMTX)
baseballnewssource.com - November 8 at 3:36 PM
finance.yahoo.com logoDimension Therapeutics Announces Presentation at the Upcoming 58th American Society of Hematology (ASH) Annual Meeting (NASDAQ:DMTX)
finance.yahoo.com - November 3 at 4:17 PM
finance.yahoo.com logoDimension Therapeutics Announces Presentation at the Upcoming 58th American Society of Hematology (ASH) Annual Meeting (NASDAQ:DMTX)
finance.yahoo.com - November 3 at 4:17 PM
finance.yahoo.com logo9:48 am Dimension Therapeutics will present a poster on AAV-based vectors for diverse therapeutic applications at ASH (NASDAQ:DMTX)
finance.yahoo.com - November 3 at 4:17 PM
finance.yahoo.com logo9:48 am Dimension Therapeutics will present a poster on AAV-based vectors for diverse therapeutic applications at ASH (NASDAQ:DMTX)
finance.yahoo.com - November 3 at 4:17 PM
globenewswire.com logoResearchers Report on New Technologies to Support Current and Next Generation HELA 2.0 AAV Manufacturing Platform (NASDAQ:DMTX)
globenewswire.com - October 18 at 9:39 AM
finance.yahoo.com logoDimension Therapeutics Announces Presentations Highlighting Advances in AAV Manufacturing at the European Society of Gene and Cell Therapy (ESGCT) Congress (NASDAQ:DMTX)
finance.yahoo.com - October 18 at 9:39 AM
finance.yahoo.com logoDimension Therapeutics Announces Presentations at the Upcoming European Society of Gene and Cell Therapy (ESGCT) Congress (NASDAQ:DMTX)
finance.yahoo.com - October 11 at 4:48 PM
publicnow.com logoDimension Therapeutics Announces Orphan Drug Designation of DTX401 for the Treatment of Glycogen Storage Disease Type Ia (GSDIa) (NASDAQ:DMTX)
www.publicnow.com - October 4 at 9:32 AM
publicnow.com logoDimension Therapeutics Announces Participation in Two Upcoming Investor Conferences (NASDAQ:DMTX)
www.publicnow.com - August 24 at 4:36 PM
capitalcube.com logoETF’s with exposure to Dimension Therapeutics, Inc. : August 24, 2016 (NASDAQ:DMTX)
www.capitalcube.com - August 24 at 4:36 PM

Social

What is Dimension Therapeutics' stock symbol?

Dimension Therapeutics trades on the NASDAQ under the ticker symbol "DMTX."

Where is Dimension Therapeutics' stock going? Where will Dimension Therapeutics' stock price be in 2017?

6 brokers have issued 1 year price targets for Dimension Therapeutics' stock. Their forecasts range from $3.00 to $20.00. On average, they anticipate Dimension Therapeutics' stock price to reach $10.83 in the next year.

When will Dimension Therapeutics announce their earnings?

Dimension Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March, 22nd 2017.

What are analysts saying about Dimension Therapeutics stock?

Here are some recent quotes from research analysts about Dimension Therapeutics stock:

  • Cantor Fitzgerald analysts commented, "We are lowering our rating to Neutral from Overweight and price target to $3 from $32, following initial results from Dimension's Phase 1/2 Study with DTX101 in Hemophilia B. Results highlighted that DTX101 will require additional optimization to be competitive with currently ongoing Hemophilia B gene therapy programs. While DTX101 was able to achieve meaningful peak FIX levels, these levels declined significantly in all patients. In addition, five of six patients demonstrated elevated levels of ALTs, which could hinder the company's ability to dose higher. Seeing the need for additional optimization for the hemophilia B program, we are moving to the sidelines and adjusting our price target." (1/31/2017)
  • According to Zacks Investment Research, "Dimension Therapeutics, Inc. is a biotechnology company which focuses on developing novel, liver-directed gene therapy treatments for severe, rare genetic disorders. The company's pipeline of programs includes DTX101, a lead gene therapy product candidate designed to deliver Factor IX, gene expression for hemophilia B; DTX301, a gene therapy product candidate for the treatment of patients with ornithine transcarbamylase deficiency; DTX401, a gene therapy program for the treatment of patients with glycogen storage disease type Ia, a disease that arises from a defect in glucose-6-phosphatase and DTX201, a gene therapy program for the treatment of hemophilia A, which are in different clinical trial stage. Dimension Therapeutics, Inc. is based in Cambridge, Massachusetts. " (1/13/2017)

Who owns Dimension Therapeutics stock?

Dimension Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Orbimed Advisors LLC (21.55%), FMR LLC (19.54%), New Leaf Venture Partners L.L.C. (8.22%), FIL Ltd (6.74%), Janus Capital Management LLC (4.42%) and State Street Corp (0.74%). Company insiders that own Dimension Therapeutics stock include K Reed Clark and Rishi Gupta.

Who sold Dimension Therapeutics stock? Who is selling Dimension Therapeutics stock?

Dimension Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Janus Capital Management LLC.

Who bought Dimension Therapeutics stock? Who is buying Dimension Therapeutics stock?

Dimension Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including New Leaf Venture Partners L.L.C., Renaissance Technologies LLC, State Street Corp and Turner Investments LLC.

How do I buy Dimension Therapeutics stock?

Shares of Dimension Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Dimension Therapeutics stock cost?

One share of Dimension Therapeutics stock can currently be purchased for approximately $1.90.

Dimension Therapeutics (NASDAQ:DMTX) Chart for Monday, February, 20, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Dimension Therapeutics (NASDAQ:DMTX)

Earnings History Chart

Earnings by Quarter for Dimension Therapeutics (NASDAQ:DMTX)

Dividend History Chart

Dividend Payments by Quarter for Dimension Therapeutics (NASDAQ:DMTX)

Last Updated on 2/20/2017 by MarketBeat.com Staff